Sabine Strehl Group

Sabine Strehl Group

Sabine Strehl
Email: Sabine.Strehl(at)

Genetics of Leukemias

Leukaemia accounts for 25-35% of all childhood cancers, and is thus the most common malignancy in children. The main research of the Genetics of Leukaemia group is focused on the detection and characterization of the genetic alterations that are involved in the pathogenesis and progression of the disease. The comprehensive analysis of specific genetic lesions serves on the one hand to determine their biological impact, and on the other to evaluate whether they may be used as predictive markers for the refinement of risk-adapted therapy.


Our research activities focus on the following sub-objectives:

  • The elucidation of the role of specific genetic alterations in the pathogenesis of childhood leukaemia.
  • The establishment of innovative cellular model systems to study the functional consequences of potential oncogenes.
  • The characterization of new and rare genetic disease entities.
  • The delineation of genetic alterations with an adverse or favourable prognostic impact, hence, the identification of patients who may benefit from more intensive or alternative therapies or for whom there might be a window of opportunity for treatment de-escalation without risking a higher relapse rate or poorer overall survival.

Specific research topics

Human induced pluripotent stem cells as novel cellular model system

Due to their self-renewal and differentiation capacities, human induced pluripotent stem cells (hiPSCs) hold considerable promise for in vitro disease modelling and preclinical drug testing. Therefore, we aim to in vitro differentiate normal and genetically modified (via CRISPR/Cas9 genome editing) hiPS cell lines towards specific hematopoietic lineages to determine whether this cellular model system may be used to study the oncogenicity and downstream effects of specific cancer-related genetic alterations in cell-type and differentiation stage-specific settings.

Identification and characterization of rare genetic subtypes

In recent years, a multitude of novel recurrent genetic rearrangements, which define specific disease entities, have emerged in childhood leukaemia. As several of the genetic lesions are cryptic and not detectable by conventional molecular technologies, we are subjecting all so far genetically uncharacterized leukaemia samples to transcriptome (RNA) sequencing and gene expression profiling. Within the frame work of the international BFM and Ponte di Legno childhood leukaemia working groups we aim to characterize these novel and rare genetic subtypes in terms of their biological properties and their clinical relevance.

Prognostic impact of specific genetic alterations

Although the risk stratification employed in the Austrian ALL- and AML-BFM trials has been proven as excellent guide for therapeutic decisions, there is still room for improvement. Hence, in national and international studies and in collaboration with the leading oncologists of the St. Anna Children's Hospital, we are assessing whether specific genetic lesions or combinations thereof are of predictive value and may in the future be implemented in the concept of risk-adapted therapy to further refine current stratification strategies.

Selected Articles

Team Genetics of Leukaemias

Dr. Sabine Strehl (PhD)

Dr. Sabine Strehl (PhD)

Group Leader

sabine.strehl(at) +43 1 40470 4020
Marion Riebler, MSc (neè M. Zeginigg)

Marion Riebler, MSc (neè M. Zeginigg)


marion.riebler(at) +43 1 40470 4023

Klaus Fortschegger, PhD

Klaus Fortschegger, PhD

Staff Scientist

klaus.fortschegger(at) +43 1 40470 4023   Read More
Dagmar Schinnerl (neé D. Denk), PhD

Dagmar Schinnerl (neé D. Denk), PhD

Bioinformatics Data Analyst

dagmar.schinnerl(at) +43 1 40470 4023

Manel Lladó Santaeularia, PhD

Manel Lladó Santaeularia, PhD

Postdoctoral Fellow

manel.llado-santaeularia(at) +43 1 40470 4023

Affiliated Clinicians

Assoc. Prof. Dr. Andishe Attarbaschi, MD Assoc. Prof. Dr. Georg Mann, MD